Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Authors
Keywords
-
Journal
Frontiers in Public Health
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-20
DOI
10.3389/fpubh.2022.996179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
- (2022) Yu Zhou et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
- (2022) Haoning Guo et al. Frontiers in Pharmacology
- Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
- (2022) Bin Wu et al. Frontiers in Pharmacology
- Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
- (2022) Yue Zhang et al. Frontiers in Pharmacology
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
- (2022) Takashi Kadowaki et al. Lancet Diabetes & Endocrinology
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database
- (2021) Faizan Mazhar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety of Semaglutide
- (2021) Mark M. Smits et al. Frontiers in Endocrinology
- A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system
- (2021) Yamin Shu et al. Expert Opinion On Drug Safety
- Safety of injectable semaglutide for type 2 diabetes
- (2020) Rajesh Peter et al. Expert Opinion On Drug Safety
- Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
- (2020) Milo Gatti et al. European Journal of Preventive Cardiology
- Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
- (2020) Ofri Mosenzon et al. POSTGRADUATE MEDICINE
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Time‐to‐onset analysis of amiodarone‐associated thyroid dysfunction
- (2019) Sayoko Kinoshita et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis
- (2018) Panagiotis Andreadis et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2018) Fang-Hong Shi et al. Frontiers in Pharmacology
- Discovery, characterization, and clinical development of the glucagon-like peptides
- (2017) Daniel J. Drucker et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Diabetes Technology & Therapeutics
- Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials
- (2014) Troels M. Jensen et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database
- (2013) Jean-Luc Faillie et al. ACTA DIABETOLOGICA
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
- (2011) Jean-Louis Montastruc et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now